CCR2 and central nervous system cancer: While these prior studies clearly support targeting CCR2+/CX3CR1+ cells as a means to treat gliomas, a greater appreciation of the immune suppressive and migratory properties of this CCR2+/CX3CR1+ cell population is needed.